AstraZeneca PLC (AZN) PEG Ratio: 0.14
Is AstraZeneca PLC’s PEG ratio high or low?
AstraZeneca PLC's PEG ratio of 0.14 is 38% below its 5-year average of 0.23, near the low end of its 5-year range (0.03–0.44).
In line with its 12-month average of 0.14.
AZN PEG Ratio Chart
AZN Average PEG Ratio Chart
AZN Current vs Average PEG Ratio Chart
AZN PEG Ratio Metrics
PEG RATIO
0.14
PEG RATIO AVG TTM
0.14
PEG RATIO AVG 3Y
0.20
PEG RATIO AVG 5Y
0.23
PEG RATIO AVG 10Y
0.33
PEG RATIO AVG 15Y
0.40
PEG RATIO AVG 20Y
0.44
CURRENT VS TTM AVG
+0.00%
CURRENT VS 3Y AVG
-31.15%
CURRENT VS 5Y AVG
-38.46%
CURRENT VS 10Y AVG
-56.92%
CURRENT VS 15Y AVG
-65.00%
CURRENT VS 20Y AVG
-67.85%
AZN Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $282.69B | 0.14 | 0.14 | 0.20 | 0.23 |
| Merck & Co., Inc. (MRK) | $298.29B | 1.81 | 0.91 | 1.19 | 0.93 |
| UnitedHealth Group Incorporated (UNH) | $368.30B | N/A | 1.61 | 1.81 | 1.65 |
| Amgen Inc. (AMGN) | $191.09B | 0.26 | 0.26 | 2.94 | 2.94 |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 4.51 | 4.57 | 4.57 | 2.77 |
| AbbVie Inc. (ABBV) | $397.12B | N/A | 4.69 | 3.25 | 2.98 |
| Gilead Sciences, Inc. (GILD) | $156.28B | 0.01 | 0.01 | 0.38 | 0.25 |
| Abbott Laboratories (ABT) | $156.15B | 3.04 | 0.11 | 0.36 | 0.87 |
| Pfizer Inc. (PFE) | $149.18B | N/A | 0.07 | 0.13 | 0.16 |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 3.17 | 3.02 | 2.60 | 2.27 |
Growth-Adjusted Valuation
PEG Ratio
0.14
P/E Ratio
27.4
AstraZeneca PLC PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC PEG Ratio FAQ
- What is the PEG ratio for AstraZeneca PLC (AZN)?
- The PEG ratio for AZN stock is 0.14.
- Is AstraZeneca PLC's PEG ratio high or low?
- AstraZeneca PLC's PEG ratio of 0.14 is 38% below its 5-year average of 0.23, near the low end of its 5-year range (0.03–0.44).
- What is the TTM average PEG ratio for AstraZeneca PLC (AZN)?
- The TTM average PEG ratio for AZN stock is 0.14.
- What is the 3Y average PEG ratio for AstraZeneca PLC (AZN)?
- The 3Y average PEG ratio for AZN stock is 0.20.
- What is the 5Y average PEG ratio for AstraZeneca PLC (AZN)?
- The 5Y average PEG ratio for AZN stock is 0.23.
- What is the 10Y average PEG ratio for AstraZeneca PLC (AZN)?
- The 10Y average PEG ratio for AZN stock is 0.33.
- What is the 15Y average PEG ratio for AstraZeneca PLC (AZN)?
- The 15Y average PEG ratio for AZN stock is 0.40.
- What is the 20Y average PEG ratio for AstraZeneca PLC (AZN)?
- The 20Y average PEG ratio for AZN stock is 0.44.
AstraZeneca PLC PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2025-12-31 | 0.14 |
| 2023-12-31 | 0.44 |
| 2022-12-31 | 0.03 |
| 2020-12-31 | 0.30 |
| 2016-12-31 | 0.80 |
| 2015-12-31 | 0.24 |
| 2011-12-31 | 0.21 |
| 2010-12-31 | 1.04 |
| 2009-12-31 | 0.38 |
| 2008-12-31 | 0.79 |
| 2006-12-31 | 0.42 |
| 2004-12-31 | 0.74 |
| 2003-12-31 | 0.00 |
| 2001-12-31 | 1.28 |
| 2000-12-31 | 0.29 |
| 1998-12-31 | 2.24 |
| 1997-12-31 | 2.98 |
| 1996-12-31 | 0.22 |
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot